Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study

European Urology Oncology(2023)

Cited 0|Views28
No score
Abstract
In this prospective cohort of 169 metastatic castration-resistant prostate cancer patients treated with radium-223, bone alkaline phosphatase shows prognostic value to identify patients more likely to live beyond 2 yr after treatment with Ra-223. Its predictive value remains to be assessed.
More
Translated text
Key words
Metastatic prostate cancer,Radium-223,Biomarkers,Bone alkaline phosphatase
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined